Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 1,741 | 1,907 | 1,629 | 1,860 | 3,074 |
| Gross Profit | 1,741 | 1,907 | 1,629 | 1,860 | 3,074 |
| Operating Expenses | 36,476 | 38,875 | 42,909 | 63,608 | 55,451 |
| Operating Income | -34,735 | -36,968 | -41,280 | -61,748 | -52,377 |
| Other Income | 2,485 | 2,898 | 3,659 | 9,595 | 4,699 |
| Pre-tax Income | -32,250 | -34,070 | -37,621 | -52,153 | -47,678 |
| Net Income Continuous | -32,250 | -34,070 | -37,621 | -52,153 | -47,678 |
| Net Income | $-32,250 | $-34,070 | $-37,621 | $-52,153 | $-47,678 |
| EPS Basic Total Ops | -0.27 | -0.29 | -0.32 | -0.44 | -0.40 |
| EPS Basic Continuous Ops | -0.27 | -0.29 | -0.32 | -0.43 | -0.40 |
| EPS Diluted Total Ops | -0.27 | -0.29 | -0.32 | -0.44 | -0.40 |
| EPS Diluted Continuous Ops | -0.27 | -0.29 | -0.32 | -0.43 | -0.40 |
| EPS Diluted Before Non-Recurring Items | N/A | -0.29 | -0.32 | -0.31 | -0.40 |
| EBITDA(a) | $-32,318 | $-34,537 | $-39,015 | $-58,465 | $-49,966 |